ORGS - Orgenesis Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.2600
+0.0800 (+1.91%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.1800
Open4.2200
Bid1.0000 x 1800
Ask4.6500 x 1400
Day's Range4.2200 - 4.2789
52 Week Range3.7800 - 9.2500
Volume17,712
Avg. Volume28,275
Market Cap68.651M
Beta (3Y Monthly)1.47
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • How Orgenesis is breaking barriers in biotech
    Yahoo Finance Video8 months ago

    How Orgenesis is breaking barriers in biotech

    Yahoo Finance's Seana Smith and Adam Shapiro talks to Vered Caplan, CEO of Orgenesis, about making it to the top in a male-dominated field, and how her company is making a name for itself in the world of biotechnology.

  • MarketWatch29 days ago

    Orgenesis shares soar 19% premarket after FDA grants orphan designation to insulin tech

    Orgenesis Inc. shares soared 19% in premarket trade Monday, after the U.S. Food and Drug Administration granted Orphan Drug Designation to the company's Autologous Insulin Producing cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy, caused by chronic pancreatitis. Orgenesis has an exclusive license for the technology from Israel's Tel Hashomer Medical Research Infrastructure and Services Ltd., that is based on the work of Professor Sarah Ferber, the company's chief scientific officer and a researcher at THM. Patients who have total pancreatectomy always suffer from diabetes, which results in lifelong insulin-dependence with the loss of endogenous insulin secretion and that of the counter-regulatory hormone, glucagon. Shares have fallen 8% in 2019, while the S&P 500 has gained 15%.

  • Those Who Purchased Orgenesis (NASDAQ:ORGS) Shares A Year Ago Have A 53% Loss To Show For It
    Simply Wall St.3 months ago

    Those Who Purchased Orgenesis (NASDAQ:ORGS) Shares A Year Ago Have A 53% Loss To Show For It

    Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of Orgenesis Inc. (NASDAQ:ORGS) have suffered share price declines over the last year. The share price is down a...

  • Will Orgenesis Inc. (ORGS) Report Negative Q1 Earnings? What You Should Know
    Zacks3 months ago

    Will Orgenesis Inc. (ORGS) Report Negative Q1 Earnings? What You Should Know

    Orgenesis Inc. (ORGS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Does Orgenesis Inc.’s (NASDAQ:ORGS) CEO Pay Compare Well With Peers?
    Simply Wall St.4 months ago

    Does Orgenesis Inc.’s (NASDAQ:ORGS) CEO Pay Compare Well With Peers?

    In 2013 Vered Caplan was appointed CEO of Orgenesis Inc. (NASDAQ:ORGS). First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider theRead More...

  • How Does Orgenesis Inc (NASDAQ:ORGS) Affect Your Portfolio Volatility?
    Simply Wall St.8 months ago

    How Does Orgenesis Inc (NASDAQ:ORGS) Affect Your Portfolio Volatility?

    If you own shares in Orgenesis Inc (NASDAQ:ORGS) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...